Clinical Trial Detail

NCT ID NCT03099174
Title This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Boehringer Ingelheim
Indications

Advanced Solid Tumor

breast cancer

lung non-small cell carcinoma

Therapies

Abemaciclib + Xentuzumab

Abemaciclib + Letrozole + Xentuzumab

Abemaciclib + Anastrozole + Xentuzumab

Abemaciclib + Fulvestrant + Xentuzumab

Age Groups:

Additional content available in CKB BOOST